Liza Landsman - Jun 23, 2021 Form 3 Insider Report for Monte Rosa Therapeutics, Inc. (GLUE)

Role
10%+ Owner
Signature
/s/ Sasha Keough, attorney-in-fact
Stock symbol
GLUE
Transactions as of
Jun 23, 2021
Transactions value $
$0
Form type
3
Date filed
6/23/2021, 09:08 PM
Previous filing
Jun 14, 2021
Next filing
Jun 24, 2021

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding GLUE Series A-2 convertible preferred stock Jun 23, 2021 Common Stock 2.72M See Note 2 F1, F2
holding GLUE Series B convertible preferred stock Jun 23, 2021 Common Stock 3.26M See Note 2 F1, F2
holding GLUE Series C convertible preferred stock Jun 23, 2021 Common Stock 669K See Note 2 F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of Series A-2 convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") is convertible into shares of the Issuer's Common Stock on a 3.5305-for-one basis. Upon the closing of the Issuer's initial public offering, all shares of Preferred Stock will convert into the number of shares of Common Stock of the Issuer shown in column 3. The Preferred Stock has no expiration date.
F2 The Reporting Person is a manager of NEA 17 GP, LLC ("NEA 17 GP"), which is the sole general partner of NEA Partners 17, L.P. ("NEA Partners 17"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. ("NEA 17"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest.